



PHARMACEUTICAL COMPANIES OF  
*Johnson & Johnson*

**Note from the Sponsor: cancelled (or early terminated) trial**

<b>Sponsor name:</b>	Janssen Vaccines & Prevention B.V.
<b>EudraCT number:</b>	2022-001015-14
<b>Protocol number:</b>	VAC18195RSV1001
<b>Clinical trial title:</b>	A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older
<b>Reasons for the Cancellation (or early termination):</b>	The Company's single-dose RSV vaccine candidate (VAC18193) has demonstrated protection against RSV-mediated disease for at least 3 seasons. In light of these data, there is no rationale to improve our single-dose RSV vaccine candidate with the approach set forth in VAC18195RSV1001, and therefore we have decided to discontinue the VAC18195RSV1001 study. We would like to assure you that there are no safety concerns nor other considerations for terminating VAC18195RSV1001.